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Abstract
Introduction: Drugs can occasionally trigger the onset of autoimmune liver disease.
Case presentation: Three Caucasian women (aged 65, 42 and 74 years old) who were receiving long-term
nitrofurantoin as prophylaxis against recurrent urinary tract infections developed hepatitic liver disease. Serological
auto-antibody profiles and liver histology appearances were consistent with autoimmune hepatitis. Two of the
patients presented with jaundice, and one required a prolonged hospital admission for liver failure. In all three
patients nitrofurantoin was withdrawn, and long-term immunosuppressive therapy with prednisolone and
azathioprine or mycophenolate was given. The patients responded well, with liver biochemistry returning to
normal within a few months.
Conclusions: Although nitrofurantoin rarely causes autoimmune hepatitis, this antimicrobial is increasingly used as
long-term prophylaxis against recurrent urinary tract infection. General practitioners and urologists who prescribe
long-term nitrofurantoin therapy should be aware of this adverse effect.
Introduction
Autoimmune liver disease is a not uncommon cause of
chronic hepatitis in women. Although autoimmune
destruction usually occurs without an identifiable trig-
ger, some drugs including methyldopa [1] and minocy-
cline [2] are associated with autoimmune liver disease.
The antimicrobial nitrofurantoin has also rarely been
implicated in autoimmune hepatitis. We report here
three patients with hepatitis in whom nitrofurantoin was
felt to be etiologically important.
Case 1
A 65-year-old Caucasian retired police woman devel-
oped non-specific symptoms of abdominal discomfort,
nausea and lethargy. She later became jaundiced, with
dark urine and pale stools. She had a past history of irri-
table bowel syndrome, chronic lumbar back pain and
recurrent urinary tract infection. Her drug history
included mebeverine 135 mg thrice daily, dosulepin 25
mg daily, lansoprazole 30 mg daily, nitrofurantoin 50
mg daily for six years, occasional paracetamol and
inhaled salbutamol, and intermittent fluconazole for
groin candidiasis. She took no herbal remedies or
unprescribed supplements and had not drunk any alco-
hol for more than 20 years.
On examination she was jaundiced, had a tender liver
edge and mild ankle edema, but no other peripheral
stigmata of liver disease. Initial blood tests revealed
deranged liver function with bilirubin 649 μmol/L (nor-
mal range 4-21), alanine transaminase 1322 U/L (10-35),
and alkaline phosphatase 227 U/L (40-150). Albumin
was low at 28 g/L (35-50), but her coagulation screen
was normal. Full blood count, electrolytes and renal
function were normal, with a platelet count of 196 ×
10
9/L.
Serological testing for hepatitis A, hepatitis B and
hepatitis C was negative. Liver ultrasound revealed unre-
markable appearances of the liver and biliary system,
with no evidence of gallstones or biliary dilatation.
Immunological tests demonstrated positive smooth mus-
cle antibody and positive anti-nuclear antibody homoge-
nous staining pattern at a titre of 1 in 320. There was
an accompanying hyper-gammaglobulinemia with ele-
vated IgG at 21.8 g/L (normal range 5.8-14) and normal
IgA and IgG levels. Double stranded DNA antibodies,
anti-mitochondrial antibodies and liver/kidney microso-
mal antibodies were not detected.
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results were strongly suggestive of autoimmune hepati-
tis. Liver biopsy was performed and this showed fibrous
expansion of portal tracts but without evidence of estab-
lished necrosis. A chronic inflammatory cell infiltrate
with interface hepatitis and piecemeal necrosis was evi-
dent in portal areas. The histological features were con-
sistent with autoimmune hepatitis (Figure 1).
Initial management consisted of oral prednisolone 25
mg daily and bone protection using alendronate once
weekly. Within a few weeks she had a good clinical
response with resolution of jaundice and lethargy. With
the exception of nitrofurantoin which was suspected of
having triggered her illness, all her regular medications
which had all been temporarily stopped during her
investigations, were restarted. Liver biochemistry
improved with bilirubin dropping from 649 to 62 μmol/
L, and alanine transaminase dropping from 1322 U/L to
118 U/L after only one month of prednisolone. The pre-
dnisolone dose was subsequently reduced and azathiopr-
ine was added as a steroid sparing agent. After two
years she remains well with normal liver biochemistry
while no longer taking prednisolone and solely taking
azathioprine 150 mg daily for her chronic hepatitis.
Case 2
A 42-year-old Caucasian woman, who worked as a
nurse, was found to have an elevated alanine transami-
nase concentration of 469 U/L (10-35), during investiga-
tion of sub-fertility. The rest of her liver biochemistry
including albumin, and her coagulation screen were nor-
mal. She had no symptoms or signs of liver disease and
her past medical history was notable only for recurrent
urinary tract infections and previous miscarriages. Her
only medications were folic acid and nitrofurantoin 50
mg daily for two years. There was no history of excess
alcohol intake nor ingestion of herbal remedies or sup-
plements. Clinical examination was unremarkable.
Further investigations revealed a very abnormal auto-
immune screen including positive anti-nuclear antibo-
dies at a titre of 1 in 640, smooth muscle antibodies at a
titre of 1 in 320 and anti-mitochondrial antibodies at a
titre of 1 in 320. Anti-Rho, extractable nuclear antibody
and rheumatoid factor were also positive. IgG levels
were elevated at 22.8 g/L, while IgA and IgM levels
were normal. Serological testing for chronic hepatitis
viruses was negative and the serum ferritin was 300 μg/
L. Liver biopsy showed marked chronic inflammation
within the portal tracts and extensive fibrosis and some
features of cirrhosis (Figure 2).
She was treated with oral steroids at an initial dose of
40 mg of prednisolone daily. Nitrofurantoin was
stopped. Since she was trying to become pregnant a
bone-protecting bisphosphonate was withheld because
of teratogenicity risks. Her liver biochemistry improved
rapidly after a few weeks of corticosteroid medication.
Plans to introduce azathioprine have been postponed
while she tries to conceive. Two years after diagnosis
she remains well with entirely normal liver biochemistry
while taking prednisolone 7.5 mg daily.
Case 3
A 74-year-old Caucasian woman with a previous history
of cholecystectomy and left nephrectomy for renal carci-
noma four years earlier, presented with jaundice, nausea,
dark urine and pale stools. Her only medication was
nitrofurantoin 100 mg daily for two years as prophylaxis
against urinary tract infections. There was no history of
Figure 1 Liver biopsy in Case 1: portal tract inflammation with
moderate to severe chronic inflammatory cell infiltrate
composed of lymphocytes with a few plasma cells
(hematoxylin and eosin × 40).
Figure 2 Liver biopsy in Case 2: severe chronic inflammation
within portal tracts (hematoxylin and eosin × 20).
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irregular liver contour, her previous cholecystectomy
and no evidence of any biliary obstruction. Clinical
examination revealed palmar erythema, a palpable liver
edge, cholecystectomy and nephrectomy scars.
Blood tests on admission showed unremarkable full
blood count (FCB), although mean corpuscular volume
(MCV) was 100, bilirubin 394 μmol/L, alanine amino-
transferase (ALT) 1423 U/L, alkaline phosphatase 207
U/L. Albumin was 29 g/L, international normalized
ratio (INR) 1.2. A computed tomography (CT) scan of
the abdomen showed no focal lesion within the liver
and no evidence of any biliary dilatation. Serological
tests were negative for hepatitis A, hepatitis B, hepatitis
C, hepatitis E, cytomegalovirus, Epstein-Barr virus and
human immunodeficiency virus (HIV). Immunoglobulin
levels showed high IgG at 22.3 g/L and IgA slightly
elevated at 4.4 g/L. Anti-nuclear antibody was strongly
positive at 1:640, but smooth muscle antibody and liver/
kidney microsomal antibodies were negative as was
the rest of the auto-antibody screen including serologi-
cal markers for systemic lupus erythematosus. Tissue
transglutaminase antibody was negative. A liver biopsy
showed striking lobular inflammation, confluent and
bridging necrosis. In addition there were some syncytial
giant cells. There was minimal portal inflammation
and minimal plasma cells. Features were consistent with
an acute hepatitis with an autoimmune component
and some features of a syncytial giant cell hepatitis
(Figure 3).
Nitrofurantoin was stopped. Prednisolone 30 mg daily
was commenced, but failed to improve her clinical or
biochemical picture. The dose was increased to 50 mg
daily, and she remained hospitalized as she became
more unwell with bilirubin reaching 430 μmol/L and
albumin dropping to16 g/L. Mycophenolate 1 g twice
daily was added. Over a period of four months her jaun-
dice subsided and at seven months after initial presenta-
tion her liver biochemistry had returned to normal,
while taking prednisolone 10 mg daily and mycopheno-
late 1 g twice daily.
Discussion
Three cases of hepatitis in women who were taking
long-term nitrofurantoin as prophylaxis against recur-
rent urinary tract infection are described. In all three
cases the serology, liver histology and clinical response
to immunosuppressive drugs were consistent with auto-
immune hepatitis.
Nitrofurantoin is widely used for both acute and
chronic management of urinary tract infections. It is
cheap and effective, with a low incidence of resistance
in common urinary pathogens; it is also safe in preg-
nancy [3]. Nitrofurantoin has been linked to autoim-
mune hepatitis, but in view of the rarity of the
association, almost all reports of the association have
been single case reports or small series [4-9]. Further
information has been obtained from national adverse
drug reaction monitoring agencies in the Netherlands
[10] and Denmark [11] and it has been estimated that
the incidence of nitrofurantoin-induced hepatic injury is
low at about three cases in 1,000,000 [12].
Liver injury secondary to nitrofurantoin has been
reported after both acute and chronic exposure and the
patterns of hepatotoxity are different. Case reports have
often reported heterogeneous patients [7], including
both acute and chronic nitrofurantoin associated liver
injury. Acute injury, which may be via a hypersensitivity
type reaction, tends to occur within weeks of drug intro-
duction [8]. Chronic hepatitis is associated with long-
term antimicrobial prophylaxis. It occurs after at least
six months treatment in 85% of cases [10], and in many
cases treatment has been ongoing for years before pro-
blems present. Anti-nuclear antibodies and anti-smooth
muscle antibodies are often present in the chronic form
of hepatitis [6] and the liver histology resembles that of
‘idiopathic’ autoimmune hepatitis.
When hepatotoxicity is a consequence of direct drug
injury, drug withdrawal alone may lead to liver recovery.
However, the chronic liver disease associated with nitro-
furantoin is likely to be mediated via an immunoaller-
genic route. Evidence for this includes the increase
incidence in women, presence of auto-antibodies and
histological appearances. Risk factors for nitrofurantoin-
triggered liver injury have been postulated and these
include advanced age (possibly related to reduced creati-
nine clearance), female sex - in common with many
Figure 3 Liver biopsy in Case 3: syncitial hepatocyte giant cell
(arrowed) with surrounding severe hydropic degenerative
change of hepatocytes and numerous neutrophils
(hematoxylin and eosin × 40).
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tion to nitrofurantoin, other drugs such as methyldopa,
dihydralazine and minocycline are also implicated in
inducing immune-mediated liver disease. In drug-
induced autoimmune liver disease it is believed that
drug metabolites act as haptens and covalently bind to
macromolecular protein carriers. In those genetically
predisposed, the altered proteins are perceived as foreign
and consequently provoke an immunological attack on
normal hepatocellular components [13].
Nitrofurantoin-induced hepatitis is commonly asso-
ciated with hyper-gammaglobulinemia [14] and with
anti-nuclear and anti-smooth muscle antibodies [6]. Our
first patient demonstrated both these antibodies, our
second patient had a widely positive autoimmune screen
and our third patient had anti-nuclear antibodies alone.
This heterogeneity of auto-antibody production is also
seen in patients with autoimmune hepatitis and no
known drug trigger. The auto-antibody status of the
three patients prior to nitrofurantoin exposure is
unknown. None of these three patients had any record
of liver auto-antibodies being checked before the onset
of their liver disease.
The natural history of nitrofurantoin-induced hepatitis is
variable. There are certainly patients who have progressed
to fatal liver disease or transplant [7-9], but it is also likely
that many cases are sub-clinical and remain undiagnosed.
Management of nitrofurantoin-triggered hepatitis
depends firstly on recognition of the causal relationship.
Prognosis is generally good if nitrofurantoin is withdrawn
early, and sometimes simply withdrawing nitrofurantoin is
sufficient to reverse the hepatic damage [7]. However,
corticosteroids are useful in patients who had persistently
abnormal liver biochemistry despite withdrawal of nitro-
furantoin. In the cases reported here, our patients had
been on nitrofurantoin for considerable periods of time
and since the biochemical, serological and histopathologi-
cal data supported an immunologically-mediated disease
process, simple withdrawal of nitrofurantoin without the
use of immunosuppressive drugs was deemed insufficient.
Thus all three of our patients were treated with predniso-
lone, resulting in a rapid improvement in the first two
cases, but a rather slow improvement in the third. Immu-
nosuppression with corticosteroids may fail to improve
patients diagnosed at a very advanced or fulminant stage
of disease. Such fatal outcomes have occurred when nitro-
furantoin either has been continued after liver dysfunction
was identified, or has been reintroduced after liver damage
was first detected [6,7].
Future re-challenge with nitrofurantoin should be
avoided since the recurrent liver dysfunction may be
persistent and even fatal. In one case repeat administra-
tion of nitrofurantoin 17 years after the initial exposure
led to recurrent liver disease [15].
H e p a t i t i si sn o tt h eo n l yp o t e n t i a l l ys e r i o u ss i d e -
effect of nitrofurantoin; it has also been associated
with pulmonary, hematological and neurological com-
plications. Nitrofurantoin induced pulmonary disease
and liver injury can occur together and it may well be
that these share a common autoimmune mechanism
[16,17]. The pulmonary disease is often the predomi-
nant feature and so those patients with interstitial
pneumonitis should have liver function tests to check
for occult hepatitis.
Conclusions
Nitrofurantoin is widely used in the long term prophy-
laxis of recurrent urinary tract infection. Serious hepatic
injury remains rare, but recognition of harm from nitro-
furantoin is crucial since early withdrawal of the drug
has been shown to result in improved prognosis. Con-
sideration should be given to monitoring liver function
tests during long term nitrofurantoin therapy.
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